Identification of a Novel Cis Element Required for Cell Density-dependent Down-regulation of Insulin-like Growth Factor-2 P3 Promoter Activity in CaCo2 Cells*

Bosong DaiDagger , Hai WuDagger , Elly Holthuizen§, and Pomila SinghDagger

From the Dagger  Department of Anatomy and Neurosciences, The University of Texas Medical Branch, Galveston, Texas 77555-1043 and § Laboratory for Physiological Chemistry, Utrecht University, Universiteitsweg 100, 3586 CG Utrecht, The Netherlands

Received for publication, August 25, 2000, and in revised form, November 8, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The activity of the exogenous, full-length insulin-like growth factor-2 (IGF-2) P3 promoter is significantly up-regulated during the logarithmic growth phase but rapidly declines in confluent CaCo2 cells undergoing differentiation. Nuclear run-on assays confirmed cell density-dependent regulation of endogenous P3 promoter. To identify regulatory elements in the P3 promoter that may be required for regulating cell density-dependent transcriptional activity, we used the methods of promoter truncation, electrophoretic mobility shift assay, DNase footprinting, and mutation analysis. The relative activity of the full-length (-1229/+140) and truncated (-1090/+140) promoter was identical, being ~19, 27, 7, and 3% of pSV-luc activity on days 3, 5, 7, and 9 of cell culture, respectively. However, truncation to -1048 resulted in complete loss of cell density-dependent down-regulation of P3 promoter activity on days 7 and 9, suggesting the presence of regulatory elements between -1091 and -1048 sequence. Further stepwise truncation to -515 did not change promoter activity. Truncation to -138/+140 resulted in complete loss of promoter activity, suggesting that the core promoter was within the -515/-138 segment. A 14-base pair footprint (-1084/-1070) was identified by DNase footprinting within the distal -1091/-1048 segment. Electrophoretic mobility shift assay with wild type and mutant probes confirmed the presence of a novel 7-base pair (CGAGGGC) (-1084/-1078) cis element (P3-D); its mutation abolished binding. Functionality of P3-D cis element was confirmed by measuring the activity of core P3 promoter ligated to distal P3 segment containing either the mutant or wild type P3-D element. We have, therefore, identified a novel cis element, P3-D, that appears to play a critical role in regulating IGF-2 P3 promoter activity in a cell density/differentiation-dependent manner.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A large percent of colon cancers overexpress IGF-21 (1-5) and contain significant concentrations of IGF-I receptor (5-7). Colon cancer-derived cell lines secrete unprocessed IGF-2, which is even more potent than the mature form (8) and is believed to contribute to autocrine growth of cancer cells (9). Since a significant percent of primary/metastatic human colon cancers express IGF-2 and IGF-I receptor (1, 3, 5, 10) and surrounding stromal/normal epithelial cells may also express IGFs (11, 12), IGFs are likely to be potent mitogenic factors for colon cancers in situ by autocrine, endocrine, and paracrine mechanisms. We and others have shown that IGF-2 is a potent autocrine growth factor for a significant percent of human colon cancer cells (4, 13). Evidence in literature strongly supports the contention that IGFs (via IGF-I receptor) play an important role not only in the proliferation/tumorigenicity of colon cancers but also in inhibiting differentiation of the cells (13-16). It is therefore important to understand the mechanisms that contribute to up-regulation of IGF-2 levels in colon cancers.

The IGF-2 gene consists of 9 exons, and the peptide is encoded by exons 7, 8, and 9 (17, 18). The gene is transcribed from four different promoters (P1-P4) (18). Multiple transcripts are synthesized as a result of alternative promoter usage and the splicing of the unique 5'-untranslated region to common coding exons (18). Enhanced levels of P3- and P4-driven IGF-2 mRNAs have been detected in many human tumors including colorectal cancers (1-4, 9, 10, 19). Increased levels of IGF-2 mRNA in neoplastic cells can be potentially accomplished by loss of imprinting, loss of heterozygosity, transcriptional activation, and/or loss of transcriptional suppression (reviewed in Ref. 20). With loss of imprinting or loss of heterozygosity (involving duplication of the active paternal allele), IGF transcripts are made from two copies instead of one, leading to ~two times higher mRNA levels. However, the expression of IGF-2 mRNA is 10-40-fold higher in colon cancer cells compared with that in normal colonocytes (1-5). Although loss of imprinting can contribute to overexpression of IGF-2, the majority of overexpression is now believed to be due to transcriptional up-regulation in several cancers (4, 13, 21, 22). Factors involved in transcriptional regulation of the IGF-2 gene in colon cancers are as yet unknown.

In previous studies we and others have used CaCo2 cells (a human colon cancer cell line) for investigating the role of the IGF system in growth and differentiation of colon cancer cells (10, 13, 15, 16, 19, 23, 24). CaCo2 cells spontaneously differentiate in culture at confluency (25) and are an ideal in vitro model for investigating cellular mechanisms involved in proliferation and differentiation of colonic cells. IGF-2 mRNA levels are significantly up-regulated during logarithmic growth of CaCo2 cells (days 3-6) in culture followed by a steep decline in confluent cells undergoing rapid differentiation (days 7-10) (13, 23). We recently reported that P3- and P4-derived transcripts were significantly up-regulated during the proliferative phase of the cells (days 3-6 in culture) and declined rapidly in cells undergoing differentiation (days 7-10); P1- and P2-derived transcripts were not detected (19). Similarly, transcriptional activity of transiently transfected P3 and P4 promoters reached peak levels by days 4-6 and declined rapidly thereafter (19). At the present time, the regulatory element(s) within the P3 and P4 promoters, which is involved in the observed cell density-dependent regulation of the promoter activity, is unknown. Since a majority of colon cancers mainly express P3-derived transcripts, we further investigated the role of the endogenous P3 promoter in regulating IGF-2 mRNA levels, in a cell density-dependent/differentiation manner using the method of nuclear run-on assays. Additionally, for the first time, we have defined the promoter segment(s) and a putative novel cis element that may play a critical role in the cell density-dependent regulation of P3 promoter activity in CaCo2 cells using the methods of transient transfection with truncated promoter-reporter constructs, electrophoretic mobility shift assay (EMSA), and DNase footprinting.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- The CaCo2 human colon cancer cell line was obtained from Dr. Jing Yu, Tufts School of Medicine, and cells were grown as monolayer cultures as previously described (13, 19). For all experimental purposes, exponentially growing cells were seeded at ~150,000 cells/35-mm cell culture dishes (Falcon, Fisher), and the cell culture medium was changed every second day with fresh growth medium containing 10% FCS.

Nuclear Run-on Assay-- Nuclei were obtained, and assays were performed by a modification of previously described procedures (26). Briefly, 7-10 × 107 CaCo2 cells, at the indicated time points, were washed 2 times in phosphate-buffered saline (4 °C). Cells were scraped and lysed in 2 ml of Nonidet P-40 buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2, and 0.5% Nonidet P-40), and nuclei were harvested and resuspended in 100 µl (~1-2 × 107 nuclei/100 µl) of glycerol storage buffer (40% glycerol, 10 mM Tris, pH 7.5, 5 mM MgCl2, 80 mM KCl, and 0.1 mM EDTA) and stored at -80 °C. Thirty µl of nuclear run-on buffer (25 mM Tris, 12.5 mM MgCl2, 750 mM KCl, 1.25 mM ATP, 1.25 mM CTP, 1.25 mM GTP) and 20 µl of [32P]UTP (3000 Ci/mmol, ICN, Costa Mesa, CA) were added to 100 µl of nuclear suspension. The transcription runoff was allowed to proceed at 30 °C for 30 min and terminated with DNase I (300 units), and CaCl2 (final concentration 1 mM) was allowed to proceed at 30 °C for 10 min. One µl of proteinase K (20 mg/ml) and 25 µl of SET buffer (5% SDS, 50 mM EDTA, 100 mM Tris, pH 7.5) were added and incubated for 30 min at 37 °C. Subsequently, 550 µl of 4 M guanidinium isothiocyanate and 90 µl of 3 M sodium acetate were added, and the mixture was extracted with phenol/chloroform/isoamyl alcohol (25:24:1). The aqueous phase was removed, and RNA was precipitated with 1 volume of isopropyl alcohol. The pellet was resuspended in 300 µl of guanidinium isothiocyanate, and RNA was reprecipitated with isopropyl alcohol. The pellet was washed with 70% ethanol, dissolved in 100 µl of TES (10 mM Tris, pH 7.2, 1 mM EDTA, 0.1% SDS), and used for hybridization. A DNA slot or dot blot apparatus was used to blot equal concentrations of linearized plasmids (10 µg) onto nitrocellulose filters (Schleicher and Schuell). The DNA plasmids used included the negative control (Bluescript II SK+ vector without insert), the Bluescript II SK+ vector (containing human 18S cDNA used as a positive control for normalizing the hybridization signals), and a plasmid containing the human IGF-2 exon 5 DNA (to measure P3 promoter-driven transcriptional activity). The plasmid DNA were linearized by appropriate restriction endonucleases and denatured with 0.2 M NaOH. The pre-hybridization and hybridization solutions consisted of 10 mM TES, 0.2% SDS, 10 mM EDTA, 0.3 M NaCl, 1× Denhardt's, 0.25 mg/ml, Escherichia coli DNA. DNA blots were pre-hybridized in hybridization buffer for 3 h at 65 °C for 36 h. Hybridization was carried out at 65 °C for 36 h. Filters were washed in 2× SSC (1× SSC = 0.15 M NaCl and 0.015 M sodium citrate) with 0.1% SDS for 10 min twice and then in 0.01× SSC with 0.1% SDS for 30 min at 60 °C before autoradiographic analysis. The nuclear run-on assay results were quantitated by densitometric analysis of the autoradiographic results using the UltroScan LX laser densitometer (Amersham Pharmacia Biotech). Relative levels of RNA on different days of cell culture were determined with the help of GelScan XL software (Amersham Pharmacia Biotech). RNA levels in each experimental blot are expressed as a ratio of the corresponding 18 S RNA blot.

Human IGF-2 P3 Expression Vectors Used for Transfections-- The IGF-2 promoter-luc constructs used for transfection are presented diagrammatically in Fig. 1. The full-length human promoter P3 DNA fragment was subcloned into the BamHI and SaII sites of the luciferase reporter gene expression vector, PSla3 (18), resulting in HUP3. Additional P3 clones containing the indicated truncated P3 fragments (Fig. 1) were derived from HUP3 either by restriction enzyme digestions with the appropriate enzymes and filling in of the protruding ends by Klenow DNA polymerase (Fig. 1) or by PCR amplification of the indicated fragments (Fig. 1). For PCR amplification, six separate 5' sense primers were used: (a1) 5'-GCGCGCGGAGGGCGAAGTGATTGAT-3' (-1090/-1070); (a2) 5'-GCGCGCGGAGGGCGAAGTGATTGAT-3' (-1048/-1012); (a3) 5'-AGGGGGGCAGGGGGGCGCGGGATTC-3' (-1006/-982); (a4) 5'-TCCCCTTGGCTAGGCTTAGGCGGC-3' (-946/-923); (a5) 5'-ACCCCCAAATTATCGTGGTGG-3' (-884/-864); primer (a6) 5'-TCCCGCCCTGATCCTCTCTCC-3' (-716/-696) along with a common 3'-antisense primer 5'-GTCGACGCGGGGCCGCCTTGCCCGA-3' (+139/+115). The full-length HUP3-luc vector (linearized) was used as template for the PCR amplifications. The PCR reaction was performed in the presence of AmpliTaq DNA polymerase (PerkinElmer Life Sciences) as described previously (27). The PCR products were subcloned into PCR 2.1 cloning vector using a TA cloning kit (Invitrogen, San Diego, CA) as per protocols provided by the supplier. Positive clones (that were determined to have the appropriate orientation of the P3 promoter DNA fragment in relation to the KpnI site on the PCR 2.1 vector) were selected and checked by DNA sequencing. The inserts were released from the PCR 2.1 vectors by XhoI and KpnI endonuclease digestion and religated into the same sites in promoterless luciferase reporter vector, pGL2-Basic (Promega, Madison, WI). The six new luciferase expression vectors, thus constructed, were termed HUP A1-HUP A6 luc vectors as shown in Fig. 1. The orientation and the sequence of the inserts were confirmed by DNA sequencing using pGL primers one, 5'-TCTATCTTATCCTACTGTAACTG-3' (~10 bp upstream from multiple cloning site of pGL-2 basic vector), and two, 5'-CTTTATGTTTTTGGCGTCTTCC-3' (~20 bp downstream from multiple cloning site of pGL-2 basic vector).



View larger version (47K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic representation of the IGF-2 promoter-luc constructs used in transient transfection assays. The restriction sites available in the P3 promoter and exon 5 were used for constructing truncated constructs HBSP3 and HAVP3 in luciferase expression vector, pSla3. Six truncated constructs are also shown (HUP3-A1-luc to HUP3-A6-luc) that were PCR-amplified from the HUP3 vector using primers a1-a6, as described under "Experimental Procedures."

DNA Transfection of CaCo2 Cells-- CaCo2 cells in culture in 35-mm dishes (as described above under cell culture) were transfected with 5-10 µg of the indicated vector DNA on days 2-8 of cell culture by the calcium phosphate precipitation method, as described previously (19, 28, 29). Cells were cotransfected with the SV40 beta -galactosidase expression vector (pSV beta -Gal vector, Promega) to normalize for transfection efficiency (19, 29). Duplicate dishes were transfected with 5 µg of luciferase expression vector (pGL2, Promega) under the transcriptional control of the SV40 promoter as a positive control (19, 29). Cells were grown in regular growth medium containing 10% FCS until 22 h before transfection. Fresh growth medium containing 10% FCS was added on alternate days until the day of transfection. Additionally, before transfection, fresh growth medium plus 10% FCS was added. Post-transfection, the cells were washed with fresh medium plus 10% FCS and cultured for 24 h followed by cell lysis for purposes of measuring luciferase and beta -Gal activities.

Luciferase and beta -Gal Assays-- Luciferase and beta -Gal were measured in the cell lysates as described by us (29). Briefly, cells were washed twice with phosphate-buffered saline and lysed using the reporter lysis buffer (Promega) as per the protocols provided by the company. Luciferase activity was measured with the luciferase assay system (Promega) using 50 µl of cell extract and 100 µl of luciferase buffer at room temperature. Luciferase activity was measured within 15 s of adding the substrate, luciferin, with Berthold AutoLumaat LB953 (Wallac-Berthold, Gaithersburg, MD). The beta -Gal assay was performed with the beta -galactosidase enzyme assay system (Promega) as per the protocols provided by the company, as described by us (29). At the end of the reaction, the absorbance of the samples was read at 420 nm in a Umax kinetic microplate reader (Molecular Devices, Menlo Park, CA).

EMSA-- Initially we conducted EMSA with double-stranded (ds) DNA fragments that were obtained by restriction digestion of the full length HUP3-luc vector, as shown in Table I. The DNA fragments were purified by agarose gel electrophoresis and labeled with [alpha -32P]ATP by T4 polynucleotide kinase (Promega). The labeled DNA fragments were separated from unincorporated nucleotides by chromatography through a G50 spin column (Amersham Pharmacia Biotech). Nuclear extracts were prepared from CaCo2 cells on the indicated days of cell culture by methods described by Abmayr et al. (30). Protein concentrations were measured, and nuclear extracts were separated into aliquots and frozen at -70 °C. EMSA was performed essentially as described by Rietveld et al. (31). Briefly, EMSA was performed in a 20-µl binding reaction containing 5-10 µg of crude nuclear extract prepared from CaCo2 cells on different days of cell culture, 5 µl of DNA probe containing ~200,000 cpm, 1 µg of poly(dI-dC), 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.05 mM EDTA, 1 mM MgCl2, 4% glycerol, and 1 mM dithiothreitol and incubated for 15 min at room temperature. For competition, a 100-200-fold excess of the unlabeled DNA probe was mixed with the radiolabeled probe before the addition of the protein extract. After incubating the samples for 15 min at room temperature, the DNA protein complexes were separated from the free DNA by electrophoresis in 5% nondenaturing polyacrylamide gels in 0.5× Tris-boric acid-EDTA buffer. The gels were dried and subjected to autoradiography in the presence of intensifying screens at -80 °C. We additionally conducted EMSA with the indicated ds oligonucleotide probes using methods that were essentially similar to that described previously (31). The oligonucleotide probes used are detailed under "Results."

DNase I Footprinting Assay-- DNase I footprinting assays were performed with the help of Core Footprinting System (Promega) by our published procedures (31). The ds DNA fragment (-1164/-871) was amplified with sense primer, 5'-AGGGACGCGGAGGAGAGGCGC TCC-3', and antisense primer, 5'-AGGATCCATTTGGGGGTCTGGGGAAACCAT-3', by PCR using HUP3-luc vector as the template. PCR products were cloned into PCR 2.1 vector by using TOPO cloning kit (Invitrogen, CA). The DNA fragment was released from the new vector by EcoRI digestion and isolated from agarose gel by using QIAEX II gel extraction kit (Qiagen, Inc.). The resulting 293-bp template was labeled with [alpha -32P]ATP by T4 DNA kinase (New England Biolabs). The labeled DNA was digested with BamHI to get a single-stranded template for the DNase footprinting assay. Unincorporated nucleotides were removed from the labeled sample by using NucTrap® probe purification columns (Stratagene). The binding reaction was set up as per the protocol provided by the manufacturer. The binding reaction (50 µl) contained 100,000 cpm of labeled DNA probe, 20 µl of nuclear protein (prepared as described above), 25 mM Tris-HCI, pH 8.0, 50 mM KCl, 6.125 mM MgCl2, 0.5 mM EDTA, 10% glycerol, and 1 mM dithiothreitol. After incubation for 20 min at 4 °C, 50 µl of 10 mM MgCl2, and 5 mM CaCl2 were added followed by the addition of 0.14 units of DNase I, and incubation was continued at room temperature for 3 min. DNase I digestion was quenched by the addition of 90 µl of stop solution (200 mM NaCl, 30 mM EDTA, 1% SDS), and the DNA template was purified by phenol/chloroform (1:1) extraction and ethanol precipitation. Samples were analyzed by electrophoresis through denaturing 6% polyacrylamide/urea sequencing gels. Gels were dried on Whatman No. 3MM paper and visualized by autoradiography. To identify the nt sequence of the footprint, we simultaneously ran a 20-bp DNA ladder (Sigma) labeled with [alpha -32P]ATP using T4 DNA kinase. The labeled DNA ladder was run along with the DNase-treated samples as a size marker by the Maxam and Gilbert G+A track method, as published previously (31).

Construction of a Homologous P3 Core-luc Construct Ligated to Either WT or Mutant Distal P3 Promoter-- To examine the functionality of the identified regulatory DNA segments within the distal P3 promoter, we used HUP3-A6-luc vector (Fig. 1) that contained a representative P3 core promoter (-712/+140). Two pairs of ~100-bp oligonucleotides were synthesized (Genemed Syn Inc.) for ligation to the homologous core P3 promoter. The WT sense and antisense oligonucleotide sequences represented -1091/-991 nucleotides of the P3 promoter. The mutant ~100-bp oligonucleotides were mutated at the -1087/-1074 nucleotide sequence by AT repeats in the sense oligo and by TA repeats in the antisense oligo. The ds-synthesized oligos contained KpnI (5') BamHI (3') overhangs for ligating to the core promoter. The HUP3-A6-luc vector was pre-digested with KpnI and BamHI. The pre-digested vector was ligated with the ds-synthesized oligos using T4 DNA ligase. The constructs were confirmed by DNA sequencing using the pGL primers as indicated above and were arbitrarily named P3-D WT- and P3-D mut-HUP3-A6-luc vectors. The WT and mutant vectors thus constructed were transfected into CaCo2 cells on days 5 and 7 along with the beta -Gal vector, and the luciferase and beta -Gal activities were measured in the cells 24 h post-transfection as described above.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Relative Levels of Endogenous P3-derived IGF-2 Transcripts in CaCo2 Cells on Days 3-11 of Cell Culture-- To determine the levels of expression of endogenous P3-derived IGF-2 mRNAs in proliferating and differentiating CaCo2 cells, nuclear run-on transcription assays were conducted in the nuclei of CaCo2 cells on consecutive days of cell culture. In four separate experiments, RNA prepared from nuclei on the indicated days of cell culture were hybridized with various probes as described under "Experimental Procedures."

Hybridization of nuclear RNA with the 18 S ribosomal DNA demonstrated a similar intensity in the signal on different days of cell culture, implying that equal amounts of RNA were used for the experiment (Fig. 2A). No specific signal other than background noise was obtained with the negative control DNA (Bluescript SK+ vector without insert). However, IGF-2 transcription was highly regulated and dependent on the differentiation status of the CaCo2 cells (Fig. 2A). A significant up-regulation in the relative abundance of IGF-2 transcripts was measured on day 5 (compared with day 3 and 4 values) when cells are in the proliferative phase. This was followed by a steep decline in the relative abundance of IGF-2 transcripts on days 6-7, when cells enter differentiation, and IGF-2 mRNA levels were minimal on days 8-11, the exponential phase of differentiation (Fig. 2A). Four independent experiments with nuclei from CaCo2 cells samples were performed using the IGF-2 and 18 S probes. Densitometric analysis of the autoradiographic data with the IGF-2 probe, normalized with the 18 S probe, is shown in bar graphs in Fig. 2B. Interestingly, the observed pattern of transcriptional activity for the endogenous IGF-2 gene is almost identical to the pattern of transcriptional activity measured with exogenous P3 promoter-reporter constructs as recently reported (19). The results thus confirm our earlier findings that reduction of IGF-2 mRNA levels in CaCo2 cells (13) reflect changes in the transcriptional activity of the exogenous (19) and endogenous (present study) IGF-2 gene caused by gradual progression of differentiation on consecutive days of cell culture.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Nuclear run-on analysis of endogenous IGF-2 gene transcription in CaCo2 cells on days 3-11 of cell culture. A, representative autoradiographs from experiments I and II from a total of four experiments are shown. The probe used for measuring IGF-2 P3-derived transcripts is described under "Experimental Procedures." As controls, 18 S ribosomal transcripts were measured simultaneously. B, the ratios of IGF-2/18 S mRNAs measured for all four experiments on different days of cell culture are shown as bar graphs. The data in the bar graphs from days 3-11 are presented as the mean ± S.D. of duplicate measurements from 2-4 separate experiments.

Relative Contribution of the Distal, Middle, and Proximal Segments of the P3 Promoter in Cell Density-dependent Regulation of the P3 Promoter Activity-- To determine if the promoter region responsible for the cell density-dependent regulation of transcription was located within the distal, middle, or proximal segment(s) of the P3 promoter, we used three IGF-2 P3 promoter constructs in transient transfection assays. HUP3-LUC, the maximal promoter (-1229/+140), and two truncated promoter fragments, HBSP3-luc (-515/+140) and HAVP3-luc (-138/+140) (Fig. 1), were used in these studies. CaCo2 cells were transfected on days 3, 5, 7, and 9 of cell culture with one of the P3 promoter constructs and with a beta -Gal expression vector to correct for transfection efficiency. To normalize the activities of the IGF-2 promoter constructs, pSV-luc was included as a positive control, and its value was arbitrarily assigned to 100%. Data from a representative experiment (from a total of three similar experiments) are presented in Fig. 3A as a percent of the pSV-luc/beta -Gal activity on different days of cell culture.



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   Transcriptional activity of the full-length and truncated IGF-2 P3-luc vectors in CaCo2 cells. A, CaCo2 cells were cotransfected with DNA from the full-length (HUP3-luc) and truncated (HBSP3-luc and HAVP3-luc) vectors (Fig. 1) and with a beta -Gal expression vector to normalize for transfection efficiency as described under "Experimental Procedures." Duplicate dishes were transiently transfected with DNA from the pSV-luc vector. The luc/beta -Gal activity for each sample was determined, and the relative activity of the P3-luc vectors is presented as a percent of the pSV-luc activity (arbitrarily assigned a 100% value) on the indicated days of cell culture. Each bar graph represents the mean ± S.E. of data obtained from three separate experiments. B, the fold increase in the activity of the HBSP3-luc vector compared with that of the full-length HUP3-luc vector (based on data presented in A) is presented as a ratio of HBSP3-luc/HUP3-luc activity on the indicated days of cell culture. a, b, and c indicate data from three separate experiments. The numbers on top of each bar graph represent the fold increase of the luc activity of construct HBSP3 compared with that of the HUP3-luc activity.

The relative activity of HAVP3 (-138/+140) was minimal on all days of cell culture, suggesting that even for basal P3 promoter activity, some core elements critical for transcription must be present upstream of position -138. On the other hand, HBSP3 (-515/+140) appeared to contain all the critical basal promoter elements and demonstrated maximal promoter activity. Surprisingly, the activity of HBSP3 was significantly higher than that of the full-length HUP3 (-1229/+140) on all days of cell culture, suggesting that specific inhibitory elements may be located between -1229 and -515. The fold increase in the activity of HBSP3 compared with that of HUP3 (as measured in 3 separate experiments, a-c, on days 3, 5, and 7 of cell culture) was determined (Fig. 3B). Although the relative activity of HBSP3 decreased 2-3-fold from days 4-5 to 7-8 of cell culture (Fig. 3A), the relative activity of HUP3 was almost abolished on days 7-10 of cell culture. The strong down-regulation of the transcriptional activity of HUP3, but not of HBSP3, suggested that the distal segment of the P3 promoter (-1229 to -515) contained a potent inhibitory element that is regulated in a cell density-dependent manner.

To further narrow down the location of the putative regulatory element(s) in the distal segment of P3 promoter, we initially measured transcriptional activity of three additional truncated constructs (HUP3-A1, HUP3-A5, and HUP3-A6) (Fig. 1) and compared the activity with that of HBSP3-luc and HAVP3-luc vectors. The results of a representative experiment (of a total of two similar experiments) are presented in Fig. 4. The transcriptional activity of HUP3-A1-luc construct was almost identical to that of the full-length HUP3-luc vector (Fig. 4), indicating that the extreme distal end of the P3 promoter (-1229 to -1091) does not contain the regulatory element(s). In contrast, further truncation to -889 (HUP3-A5-luc) resulted in a strong increase (up to 10-fold) of promoter activity, suggesting that the cell density-dependent regulation of P3 was lost on truncation of the segment between -1091 to -889. Further truncation of the distal segment to -712 (HUP3-A6-luc) showed no additional effects on transcriptional activity. These results suggested that the P3 promoter contained regulatory element(s) between -1091 and -889 (relative to the CAP site) that may be involved in silencing of the promoter by many fold. More importantly, the cell density-dependent regulation of the P3 promoter was lost on removal of the distal segment between -1091 and -889 (as in HUP3-A5 vector). To further narrow down the location of the regulatory element, additional truncated constructs between -1091 and -889 were generated as shown in Fig. 1. Transient transfection studies with HUP3-A2-luc (-1048/+140), HUP3-A3-luc (-1006/+140), or HUP3-A4-luc (-946/+140) demonstrated that the luciferase activity of all these truncated constructs was identical to that shown in Fig. 4 for HUP3-A5-luc vector (-889/+140) on days 3-9 of cell culture, indicating that the putative distal regulatory element was between -1090 and -1048 sequence of the P3 promoter (data not shown). To further confirm the presence of putative DNA binding sites in the distal P3 promoter, we conducted DNase footprinting and EMSA studies as described below.



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Transcriptional activity of the truncated constructs of the IGF-2 P3 promoter in CaCo2 cells on days 3-9 of cell culture. Five truncated constructs of the distal segment of the P3 promoter were generated as described under Fig. 1 and used in transient transfection studies as per methods described under "Experimental Procedures." CaCo2 cells on different days of culture were cotransfected with the beta -Gal expression vector, and the ratio of luc/beta -Gal was determined at each time point for the various vectors. The luc/beta -Gal values on day 5 with the HBS-luc vector were arbitrarily assigned a 100% value. All other values are presented as a percent of that measured with the HBS-luc vector on day 5. Data from two separate experiments are presented as bar graphs. Data represent the mean of 4-5 measurements from two separate experiments, wherein individual values varied by <10%.

The Distal P3 Promoter Fragment Contains a Specific DNA-Protein Complex-- We initially conducted EMSA with relatively large (100-400 bp) P3 promoter DNA fragments covering the entire distal to middle promoter (Table I). Using fragments 1, 3, and 4 as probes, similar patterns were observed for extracts from proliferating and post-confluent CaCo2 cells (data not shown). Only fragment 2 (-1090/-656) demonstrated significant differences in the binding pattern of nuclear proteins from proliferating (day 5) versus post-confluent (day 10) CaCo2 cells (Fig. 5A). A unique and specific DNA-protein complex (a) was present in proliferating cells (day 5) that was absent in post-confluent (day 10) cells.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Restriction fragments of P3 promoter used as EMSA probes



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 5.   Localization of a differentiation-dependent DNA-protein complex. A, EMSA of 32P-labeled IGF-2 P3 DNA fragment 2 (-1090/-656) (Table I) with nuclear proteins prepared from CaCo2 cells on either day 5 (lane 1) or day 10 (lane 2) of culture. Complex a is seen only in day-5 samples. All other complexes are common to day-5 and day-10 samples. Band e is free 32P-labeled probe. B, EMSA with 32P-labeled ds oligonucleotide probe (-1090/-1065) in the presence of nuclear proteins from CaCo2 cells on different days of culture in the presence or absence of excess unlabeled probe. Autoradiograph of EMSA with nuclear protein samples from days 5-14 (lanes 2-4) using the radiolabeled 25-bp oligonucleotide probe in the presence (lane 1) or absence (lanes 2-4) of a 100-fold excess of unlabeled homologous probe is shown. Lane 1, D5 sample in the presence of 100-fold excess of unlabeled ds 25-bp probe; lane 2, D5 (50 µg) nuclear protein; lane 3, D10 (50 µg) nuclear protein; lane 4, D14 (50 µg) nuclear protein. Complex a was prominent in D5 samples (lane 2), whereas it was significantly reduced in D10 samples (lane 3). Complex a was minimally observed in day 14 samples (lane 4). The binding of proteins in day-5 samples was specific and completely displaced by excess unlabeled probe, as shown in lane 1.

Based on the above truncation and EMSA results, a DNA fragment (-1164/-871) containing the putative regulatory element was used as a radiolabeled probe for DNase1 footprinting experiments to confirm the presence of the binding site in this distal segment. A specific DNA footprint was obtained with nuclear proteins from proliferating day-5 samples but not from day-10 samples. Positive data with day-5 results are shown in Fig. 6. The 14-bp-nt sequence of the footprint was identified with the help of a 20-bp DNA ladder co-run with the samples as described under "Experimental Procedures" and is shown in Fig. 6.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   DNA footprint of a distal fragment of IGF-2-P3 promoter. A ds DNA fragment (-1164/-871) was generated and used in the DNase 1 footprinting assay, as described under "Experimental Procedures," in the presence of nuclear proteins from day-5 and day-10 CaCo2 cells. No footprint was visible with day-10 samples, whereas a specific footprint was visible with day-5 samples in two separate experiments. A representative autoradiograph of DNA footprint of a total of 2 autoradiographs from 2 experiments with day-5 samples is shown. A labeled DNA ladder was co-run with the DNase-treated samples as a size marker, and the nt sequence of the DNase-protected site was determined by Maxam and Gilbert G+A track method, as published previously (31, 35). A 14-bp region (-1084/-1070) with the indicated sequence was specifically protected from DNase 1 digestion (containing the putative P3-D binding site) in the presence of day-5 samples (lanes 1 and 2). Lanes 3 and 4, DNA samples run in the absence of nuclear proteins. The size of the DNA markers that were co-run with the samples is indicated on the right-hand side with arrows. The 5'/3' direction of the DNA probe, used in the footprint assays, is indicated by the arrows facing up and down. On the left, the nt sequence of the DNA footprint is shown.

As a final confirmatory step, we used a 25-bp ds oligonucleotide sequence (-1090/-1065) encompassing the 14-bp DNA footprint (Fig. 6) for EMSA analysis with CaCo2 samples, prepared from proliferating versus post-confluent cells (Fig. 5B). Using the 25-bp ds oligonucleotide as a probe, one DNA-protein complex (a) was prominently present in day-5 samples from proliferating cells (lane 2), and this band was significantly reduced in confluent day-10 cells (lane 3) and almost absent in day-14 cells (lane 4). In the presence of excess unlabeled probe, no complex was observed (lane 1), indicating that the binding was specific. To confirm that promoter sequences 5' to -1090 and 3' to -1065 did not contain any other putative DNA binding sites, we also conducted EMSA with several other 20-25-bp oligonucleotide probes that contained sequences between -1229 to -1093 at the 5' end and between -1063 to -999 at the 3' end of the putative regulatory element; no binding was observed with sequences that were either 5' of -1091 or 3' of -1063 (data not shown).

Since DNA footprinting studies also suggested the presence of a putative binding site within the -1090/-1065 segment of the P3 promoter, we focused on identifying the core binding element within this region by mutation analysis of the -1090/-1065 EMSA probe. Mutation of the 25-bp -1090/-1065 EMSA probe at the 5' end (between -1090 and -1086) or at the 3' end (between -1075 and -1065) had no effect on the binding of the mutant probes to day-5 nuclear proteins (data not shown). However, mutations between -1086 and -1075 had significant effects on the binding to day-5 samples (Fig. 7). Binding of day-5 samples to mutants M-1 and M-4 was slightly reduced by ~20%. Binding was significantly decreased by ~40 to >60% to mutants M2, M3, and M5. Since the mutations in M2, M3, and M5 overlapped within the region of -1084 and -1078, we mutated all 6 base pairs between this segment in mutant M6, which resulted in complete loss of binding (Fig. 7). The results with the mutant probes suggest that the core of the binding element is present within -1084/-1078 of the P3 promoter. Computer analysis of the sequence (GAGGGC) using the GeneTool software program (LifeScience Software Resource, Long Lake, MN) did not demonstrate any homology with the known cis elements for various transcriptional factors. The GAGGGC sequence may thus represent a novel cis element (arbitrarily named P3-D) that specifically and differentially binds nuclear proteins from proliferating CaCo2 cells.



View larger version (52K):
[in this window]
[in a new window]
 
Fig. 7.   EMSA with WT and mutant (M1-M6) probes. EMSA was conducted with a 25-bp ds oligonucleotide probe (-1090/-1065) that had either a WT sequence or had mutated sequences (underlined and bold in M1-M6 probes) in the presence of nuclear samples from day-5 CaCo2 cells. An autoradiograph of the resulting EMSAs with WT or M1-M6 probes is shown in the top panel. A single band of oligos bound to day-5 nuclear proteins was seen with WT and mutant probes other than with the M6 probe; the pattern of binding was identical to that seen in Fig. 5B with the WT probe. The relative density of the WT band was arbitrarily assigned a 100% value, and the relative density of the bands in the presence of M1-M6 probes is presented as a percent of that measured with the WT probe and is shown as bar graphs. Lanes 1-7, relative density of binding to WT, M1, M2, M3, M4, M5, and M6 probes, respectively. The data are from a representative experiment of two similar experiments. That the binding to the probe was completely abolished on mutation of six nt (M6 probe) (lane 7) suggests the core of the binding element is present between -1084 and -1078 as shown by the black bar above the WT sequence. The hatched bar below the WT sequence represents nt sequence of the DNA footprint, as shown in Fig. 6.

To confirm a regulatory function of the identified regulatory element within the distal DNA segment of P3 promoter, we used either the WT or mutant P3-D HUP3-A6-luc vector in transfection studies, as described under "Experimental Procedures." The results with the WT and mutant P3-D HUP3-A6-luc vectors is presented in Table II; the activity of the full-length HUP3-luc vector is presented for comparison. As can be seen from the table, the presence of the distal P3 promoter segment, containing the WT P3-D element, significantly reduced the transcriptional activity of the core HUP3-A6 promoter by ~80-90%, and the activity was similar to that of the full-length HUP3 promoter. On the other hand, transcriptional activity of mutant P3-D HUP3-A6-luc vector, which was mutated at the P3-D element, was reduced only slightly compared with the activity of the parent HUP3-A6-luc vector. Importantly, transcriptional activity of the WT P3-D HUP3-A6 promoter mimicked the activity of the full-length HUP3 vector and was similarly down-regulated in day-7 samples. These results confirm the functional significance of the P3-D element and once again suggest a negative role of the P3-D element in regulating the transcriptional activity of the P3 promoter in a cell density-dependent manner.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Percent change in the ratio of luc/beta -Gal activity of core P3 promoter ligated to distal P3 segment containing either wild type or mutated P3-D element



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In a previous study, we could show by transient transfection studies that transcription of the P3 promoter of the IGF-2 gene is dependent on the growth phase of CaCo2 cells. Transcription was significantly up-regulated during logarithmic growth of the cells and rapidly declined in confluent cells undergoing differentiation (19). In the present study, we show that the transcriptional activity of the endogenous IGF-2 gene is identical to that of the exogenously transfected IGF-2 P3 promoter. By applying nuclear run-on assays at different stages of CaCo2 cell growth it was confirmed that the transcriptional activity of the endogenous IGF-2 P3 promoter was significantly up-regulated during the proliferative phase of cell growth (days 4-6) followed by a steep decline in transcriptional activity during the differentiation phase (days 7-11) (Fig. 2). This confirms our hypothesis that the endogenous IGF-2 levels in CaCo2 cells are regulated mainly at the transcriptional level in a cell density and differentiation-dependent manner.

Several functional regulatory elements are present in the proximal segment (-238/+140) of the human IGF-2 P3 promoter (32). P3 contains a TATA-box and a CAAT-box sequence, and both are bound by their cognate factors. Furthermore, several Sp1 sites are present in the proximal promoter, which is very GC-rich. Other zinc finger transcription factors such as the early growth response proteins Egr-1 and Egr-2 can also bind to multiple sites in the proximal promoter, thereby activating transcription (20, 32). Interestingly, the Wilms' tumor WT-1 gene product, a tumor suppressor protein, also recognizes the Egr binding sites in the proximal promoter and suppresses the transcriptional activity of the IGF-2 P3 promoter by binding to Egr-l/WT-1 consensus sequences (33). The absence of WT-1 is associated with overexpression of IGF-2 in Wilms' tumor (20). Other transcription factors that bind the proximal segment of the P3 promoter downstream of position -288 include p53 (34), the P3-4 cis element-binding proteins (35, 36), and AP2 (22, 31) (reviewed in Ref. 37).

Transcription factors and cis elements that may be involved in the transcriptional regulation of the P3 promoter in human colon cancer cells have yet to be identified. In the current study we observed that the distal segment of the P3 promoter, upstream of nucleotide -1048, was required for the cell density and differentiation-dependent regulation of IGF-2 transcription. Truncated promoter-luc constructs that lacked the distal segment 5' of -1048 did not reveal any differentiation-dependent down-regulation of the P3 promoter in CaCo2 cells. Additionally, down-regulation cannot be caused by the known tumor suppressor gene products because CaCo2 cells lack both wtp53 (38) and WT-1 proteins.2 Still the transcriptional activity of the P3 promoter was significantly down-regulated in a cell density-dependent manner. It thus appears unlikely that potential transcription factors identified to date that bind the proximal segment (-288/+140) of the P3 promoter play a role in the density/differentiation-dependent down-regulation of the transcriptional activity of IGF-2 P3 promoter in CaCo2 cells. Instead, the results of the present study with transient transfection assays of truncated IGF-2 P3 promoter-luc vectors suggest the novel possibility that the distal segment of the P3 promoter contains cis elements that are involved in suppressing the transcriptional activity of IGF-2 P3 promoter in a cell density-dependent manner. An important finding was that the transcriptional activity of the truncated P3 promoter that lacks the distal segment (-1091 to -1048) was enhanced by severalfold at all phases of cell growth. It thus appears likely that promoter sequences between -1091 and -1048 contain cis elements, which in the presence of specific transcription factors, confer regulated differentiation-dependent transcription activity to the promoter.

The promoter segments between -1048 and -515 appeared to lack any significant regulatory elements, since further truncation of the P3 promoter was not accompanied by any additional changes in the promoter activity compared with the activity of the HUP3B-luc vector. The activity of the HAVP3-luc vector (-138/+140) was significantly reduced to almost negligible levels on all days of cell culture. The segment between -515 and -138 nucleotide thus appears to contain a strong regulatory element(s), in the absence of which the transcriptional activity of the promoter was completely abolished in CaCo2 cells. The middle and proximal segments of the P3 promoter together (-515 to +140) may therefore represent the core promoter. As stated above, several cis elements have already been identified in the proximal segment of the IGF-2 P3 promoter (32). It is likely that some of these factors, such as Sp1 and Egr, also play an important role in the unregulated transcriptional activity of the IGF-2 gene in CaCo2 cells. The distal segment of the P3 promoter, however, appears to be critically required for observing down-regulation of P3 promoter activity in a cell density/differentiation-dependent manner in CaCo2 cells.

Using the methods of EMSA and DNase footprinting, we have identified a putative cis element (CGAGGGC, arbitrarily named P3-D) in the distal segment of the IGF-2 P3 promoter that specifically binds nuclear proteins from proliferating CaCo2 cells. In addition, the promoter truncation studies indicated the presence of physiologically relevant regulatory element(s) in this distal segment of the P3 promoter, encompassing the sequences indicated in the EMSA and DNase footprinting studies. Transcriptional activity of core P3 promoter-reporter vector was significantly reduced on ligation with distal P3 promoter sequences containing the WT-P3-D element; mutation of P3-D element in the ligated sequence did not reduce the activity of the core promoter significantly. These results further confirmed our findings that the distal segment encompassing the putative P3-D regulatory element was indeed functional and down-regulated the activity of the core promoter in a cell density-dependent manner. The sequence identified by DNase footprint (-1084/-1070) and by mutational analysis with EMSA probes (-1084/-1078) did not demonstrate any homology with the consensus sequences of known transcriptional factors as determined with the help of the gene-runner program (Hastings Software, Inc.) and the Gene-Tool program. It is therefore possible that the identified sequence represents a novel cis element (P3-D element) that is importantly involved in the differentiation-dependent down-regulation of the IGF-2-P3 promoter in CaCo2 cells.

In summary, our studies suggest the presence of a 7-bp regulatory element in the distal portion of the P3 promoter that is involved in silencing IGF-2 gene expression in colonic cells undergoing differentiation. We hypothesize that native proteins (that are perhaps expressed in a cell differentiation-dependent manner) bind to the putative P3-D regulatory element in the distal segment of the P3 promoter to either suppress the down-regulation of IGF-2 expression (during proliferation) or to silence IGF-2 expression (during differentiation); our studies so far support the former model. The cytokines interleukin-4 and transforming growth factor beta -1 significantly reduce IGF-2 mRNA levels in IGF-dependent colon cancer cells (39), but mechanisms mediating the inhibitory effects have yet to be investigated. These studies, however, suggest that specific cytokines can down-regulate the expression of the functional IGF-2 promoters in colon cancer cells, lending support to the possible presence of native transcriptional suppressor proteins that perhaps mediate the inhibitory effects of certain cytokines and that are perhaps endogenously regulated in a differentiation-dependent manner in CaCo2 cells. Lack and/or overexpression of native transcription factors in colon cancer cells is speculated to result in continued expression of IGF-2, associated with loss of differentiation.


    ACKNOWLEDGEMENTS

The secretarial help of Jean Rice is gratefully acknowledged and the technical support of Azar Owlia is gratefully acknowledged.


    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA60087 and CA72992 (to P. S.) and John Sealy Memorial Foundation Grant 454690 (to B. D.). Part of this study was published in its preliminary form as an abstract (Dai, B., Wu, P. H., Holthuizen, E., and Singh, P. (1999) in Proceedings of The Digestive Diseases Week, Abstr. 3777, American Gerontological Association, Orlando, FL).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom all reprint requests should be addressed: Dept. of Anatomy and Neurosciences, 10.138 Medical Research Bldg. 1043, University of Texas Medical Branch, Galveston, TX 77555-1043. Tel.: 409-772-4842; Fax: 409-772-1861; E-mail: posingh@utmb.edu.

Published, JBC Papers in Press, December 8, 2000, DOI 10.1074/jbc.M007789200

2 B. Dai, P. H. Wu, E. Holthuizen, and P. Singh, unpublished data.


    ABBREVIATIONS

The abbreviations used are: IGF-2, insulin-like growth factor-2; beta -Gal, beta -galactosidase; bp, base pair(s); ds, double-stranded; EMSA, electrophoretic mobility shift assay; luc, luciferase; nt, nucleotide(s); WT, wild type; TES, N-tris(hydroxymethyl)-2-aminoethanesulfonic acid; FCS, fetal calf serum; PCR, polymerase chain reaction.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Tricoli, J. V., Rall, L. B., Karakousos, C. P., Herrera, L., Petrelli, N. J., and Bell, G. I. (1986) Cancer Res. 46, 6169-6173[Abstract]
2. Werner, H., and LeRoith, D. (1996) Adv. Cancer Res. 68, 183-222[Medline] [Order article via Infotrieve]
3. Winkler, R., Delacroix, L., Bensbaho, K., Collette, J., and Hodzic, D. (1999) Horm. Metabol. Res. 31, 148-154[Medline] [Order article via Infotrieve]
4. Lamonerie, T., Lavialle, C., De Galle, B., Binoux, M., and Brison, O. (1995) Exp. Cell Res. 216, 342-351[CrossRef][Medline] [Order article via Infotrieve]
5. Frejer, S., Weiss, O., Eran, M., Flyvbjerg, A., Dahan, R., Nephesh, I., Safra, T., Shiloni, E., and Raz, I. (1999) Gut 44, 704-708[Abstract/Free Full Text]
6. Singh, P., Narayan, S., Guo, Y.-S., and Chandrasekhar, Y. (1991) In Vitro Cell. Dev. Biol. 27, 755-758
7. Guo, Y.-S., Narayan, S., Chandrasekhar, Y., and Singh, P. (1992) Gastroenterology 102, 1101-1108[Medline] [Order article via Infotrieve]
8. Perdue, J. F., LeBon, T. R., Kato, J., Hampton, B., and Fujita-Yamaguchi, Y. (1991) Endrocrinology 129, 3101-3108[Abstract]
9. Li, S.-L., Goko, H., Xu, Z.-D., Kimura, G., Sun, Y., Kawachi, M. H., Wilson, T. G., Wilczynski, S., and Fujita-Yamaguchi, Y. (1998) Cell Tissue Res. 291, 469-479[CrossRef][Medline] [Order article via Infotrieve]
10. Singh, P., Yallampalli, C., Dai, B., Rajaraman, S., and Xu, Z. (1994) Am. J. Physiol. 267, G608-G617[Abstract/Free Full Text]
11. Simmons, J. G., Pucilowska, J. B., and Lund, P. K. (1999) Am. J. Physiol. 39, G817-G821
12. Kawamoto, K., Onodera, H., Kan, S., Kondo, S., and Imamura, M. (1999) Cancer 85, 18-25[CrossRef][Medline] [Order article via Infotrieve]
13. Singh, P., Dai, B., Yallampalli, U., Lu, X., and Schroy, P. (1996) Endocrinology 137, 1764-1774[Abstract]
14. Baserga, R., Hongo, A., Rubini, M., Prisco, M., and Valentinis, B. (1997) Biochim. Biophys. Acta 1332, 105-126[CrossRef]
15. Zarrilli, R., Romano, M., Pignata, S., Casola, S., Bruni, C. B., and Acquaviva, A. M. (1996) J. Biol. Chem. 271, 8108-8114[Abstract/Free Full Text]
16. Zarrilli, R., Pignata, S., Apicella, A., Di Popolo, A., Memoli, A., Ricchi, P., Salzano, S., and Acquaviva, A. M. (1999) Gastroenterology 116, 1358-1366[Medline] [Order article via Infotrieve]
17. Holthuizen, P., LeRoith, D., Lund, P. K., Roberts, C. T., Jr., Rotwein, O., Spencer, E. M., and Sussenbach, J. S. (1991) in Modern Concepts in Insulin-like Growth Factors (Spencer, E. M., ed) , pp. 733-736, Elsevier Science Publishing Co., Inc., New York
18. van Dijk, M. A., van Schaik, F. M. A., Bootsma, H. J., Holthuizen, P., and Sussenbach, J. S. (1991) Mol. Cell. Endocrinol. 81, 81-94[CrossRef][Medline] [Order article via Infotrieve]
19. Singh, P., Dai, B., Given, R. L., Lu, X., and Holthuizen, P. E. (1998) Gastroenterology 114, 1221-1229[Medline] [Order article via Infotrieve]
20. Toretsky, J. A., and Helman, L. J. (1996) J. Endocrinol. 149, 367-372[Abstract/Free Full Text]
21. Hodzic, D., Delacroix, L., Willemsen, P., Bensbaho, K., Collette, J., Broux, R., Lefebvre, P., Legros, J. J., Groteclaes, M., and Winkler, R. (1997) Horm. Metab. Res. 29, 549-555[Medline] [Order article via Infotrieve]
22. Zhang, L., Zhan, S., Navid, F., Li, Q., Choi, Y. H., Kim, M., Seth, P., and Helman, L. (1998) Oncogene 17, 1261-1270[CrossRef][Medline] [Order article via Infotrieve]
23. Zarrilli, R., Pignata, S., Romano, M., Gravina, A., Casola, S., Bruni, C. B., and Acquaviva, A. M. (1994) Cell Growth Differ. 5, 1085-1091[Abstract]
24. MacDonald, R. G., Schaffer, B. S., Kang, I. J., Hong, S. M., Kim, E. J., and Park, J. H. Y. (1999) J. Gastroenterol. Hepatol. 14, 72-78[CrossRef][Medline] [Order article via Infotrieve]
25. Peterson, M. D., and Moosker, M. S. (1992) J. Cell Sci. 102, 581-600[Abstract]
26. Greenberg, M. E. (1994) in Current Protocols in Molecular Biology (Ausubel, F. M. , Brent, R. , Kingston, R. E. , Moore, D. D. , Seidman, J. G. , Smith, J. A. , and Struhl, K., eds) , pp. 4.101-4.109, John Wiley & Sons, Inc., New York
27. Singh, P., Xu, Z., Dai, B., Rajaraman, S., Rubin, N., and Dhruva, B. (1994) Am. J. Physiol. 266, G459-G468[Abstract/Free Full Text]
28. Singh, P., Dai, B., Dhruva, B., and Widen, S. (1994) Cancer Res. 54, 6563-6570[Abstract]
29. Dai, B., Widen, S., Mifflin, R., and Singh, P. (1997) Endocrinology 138, 332-343[Abstract/Free Full Text]
30. Abmayr, S. M., and Workman, J. L. (1988) in Current Protocols in Molecular Biology (Ausubel, F. M. , Brent, R. , Kingston, R. E. , Moore, D. D. , Seidman, J. G. , Smith, J. A. , and Struhl, K., eds) , pp. 12.1.1-12.1.9, John Wiley & Sons, Inc., New York
31. Rietveld, L. E. G., Koonen-Reemst, A. M. C. B, Sussenbach, J. S., and Holthuizen, P. E. (1999) Biochem. J. 338, 799-806[CrossRef][Medline] [Order article via Infotrieve]
32. Holthuizen, P. E., Steenbergh, P. H., and Sussenbach, J. S. (1999) in Molecular Biology, Physiology, and Clinical Applications (Rosenfeld, R. G. , and Roberts, C. T., eds) , pp. 37-61, Humana Press Inc., Totowa, NJ
33. Drummond, I. A., Madden, S. L., Rohwer-Nutter, P., and Bell, G. I. (1992) Science 257, 674-678[Medline] [Order article via Infotrieve]
34. Zhang, L., Kashanchi, F., Zhan, Q., Zhan, S., Brady, J. N., Fornace, A. J., Seth, P., and Helman, L. J. (1996) Cancer Res. 56, 1367-1373[Abstract]
35. Rietveld, L. E. G, Holthuizen, P., and Sussenbach, J. S. (1997) Biochem. J. 327, 689-697[Medline] [Order article via Infotrieve]
36. van Dijk, M. A., Holthuizen, P., and Sussenbach, J. S. (1992) Mol. Cell. Endocrinol. 88, 175-185[Medline] [Order article via Infotrieve]
37. Singh, P. (2000) J. Clin. Ligand Assay 23, 214-232
38. Djelloul, S., Forgue-Lafitte, M. E., Hermelin, B, Mareel, M., Bryneel, E., Baldi, A., Giordana, A., Chastre, E., and Gespach, C. (1997) FEBS Lett. 406, 234-242[CrossRef][Medline] [Order article via Infotrieve]
39. Lahm, H., Anstad, P., Yilmaz, A., Fischer, J. R., Givel, J. C., Odartchenki, N., and Sordat, B. (1996) Biochem. Biophys. Res. Commun. 220, 334-340[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.